BioWorld MedTech

Nov. 19, 2013

Deals roundup: CareFusion to acquire Vital Signs from GE for $500 million

CareFusion (San Diego) reported the signing of a definitive agreement to acquire the Vital Signs (Totowa, New Jersey) division of GE Healthcare (Chalfont, UK) for $500 million. Read More

Indian government seeking reforms: India looks to better regulate devices for the third time

Financings roundup: Solta secures $40 million for working capital and growth

Washington roundup: Device-intensive procedures named in report on outlier pay

American Academy of Ophthalmology meeting: IRIS Registry makes debut, pinpoints EHR opportunities

Agreements/contracts: Qiagen in diagnostics accord with Eli Lilly

HIT roundup: AliveCor launches its mobile heart health service

Grants roundup: NYU gets $10M from NIH for ISCHEMIA-CKD study

People in the News

Product Briefs

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for July 13, 2026.

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

NRF2 activators reported in Vailima Peninsula patent

BioWorld Science

Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...